AimwellBio Reference Document · Edition 01

The Biopharma AI Risk Brief.

Seven ways unsupported scientific intelligence can enter regulatory, clinical, board, and investor workflows — and what a defensible review layer is built to catch before the decision is made.

7 risk patterns · operating context
Where each shows up · decision cost
Self-audit checklist · before your next brief
What review catches · per AimwellBio surface

Written for regulatory affairs, medical affairs, clinical development, biopharma operators, healthcare investors, board members, and AI governance leads. Not a marketing piece. A reference document for teams that have already noticed the problem.

Request the Brief

Open access for credentialed professionals.

We will reply with the PDF + an optional 30-minute review on a brief of your choosing. No sales sequence, no list-trading. Privacy.

Prefer to read it now without giving us your email? Direct link →
Inside · Seven Risk Patterns

Where unsupported intelligence enters the workflow.

Each risk includes the pattern, where it shows up, the decision cost when it goes wrong, and which AimwellBio surface is built to catch it.

Risk 01
Fabricated citations in AI-generated literature summaries
Catches: Shield
Risk 02
Stale regulatory guidance treated as current
Catches: Signal
Risk 03
Phase II→III extrapolation without enrollment-failure pattern check
Catches: Verdict
Risk 04
Competitive readouts that miss recent label-narrowing signals
Catches: Signal
Risk 05
Investor memos built on unverified FDA decision claims
Catches: Verdict
Risk 06
Clinical workflow tools surfacing AI summaries without source-trace
Catches: FHIN + Shield
Risk 07
Board memos aggregating fragmented sources without adversarial challenge
Catches: Verdict

This brief is what AimwellBio hands to every team it works with — before any commercial conversation.

If the seven patterns describe a problem your team has already noticed, the Brief gives you a structured way to describe it to your colleagues, your counsel, and your procurement reviewers. If they don't, you can hand it back and we move on. Either way, you keep it.

Edition 01 · May 2026 · Decision-support reference · Not medical, legal, or investment advice